Facts & Figures
Science for a better life - Medical Progress for the Benefit of the Patient
Facts and Figures at a glance
| Research expenses 2011 | 1,984 € million (2010: 2,066 € million) |
| Proportion of total Bayer group research expenses 2011 | 64,4% |
| Employees in Research & Development | 7,700 |
| Main research locations | Berlin and Wuppertal, Germany, Berkeley, USA, Bejing, CHina |
| Research focus |
|
Research activities 2011
In 2011 we invested €1,948 million (2010: €2,066 million) in research and development in the Pharmaceuticals and Consumer Health segments. This represented 66.4% of the Bayer Group’s entire research and development spending and was equivalent to 11.3 percent (2010: 12.2 percent) of HealthCare sales. At the end of 2011, some 7,700 employees of the HealthCare subgroup were working in research and development.
Research and development expenses in the Pharmaceuticals segment amounted to €1,556 million (2010: €1,684 million), or 15.6 percent (2010: 16.9 percent) of segment sales. The decline was mainly due to lower development costs following the successful completion of the majority of Phase III studies for our anticoagulant Xarelto™. Our research and development outlay underscores our focus on growth through innovation.
Drug discovery in the Pharmaceuticals segment is concentrated in the areas of cardiology and oncology, along with gynecological treatments and hematology. Other areas of focus are inflammatory processes and ophthalmology. In addition, we are strengthening our established products through lifecycle management, an example being the development of innovative administration forms for contraceptives.
Research locations
Research activities and capacities are concentrated at three sites in Berlin and Wuppertal, Germany, and Berkeley, California, United States. Work in Berlin and Wuppertal mainly focuses on the discovery, optimization and development of new active substances. Research is also carried out at these sites in the fields of drug metabolism, pharmacokinetics, toxicology and clinical pharmacology. Berkeley is a major research and development center focused on biologicals for hematology, such as Kogenate™. We also operate further research centers, such as those in Beijing, China.
Search
Bayer HealthCare Links
Bayer scientific magazine
Clinical trials
Information about clinical studies is available at database of